Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Allogene Therapeutics Inc

Healthcare US ALLO

1.9USD
0.02(1.06%)

Last update at 2026-06-12T20:14:00Z

Day Range

1.861.94
LowHigh

52 Week Range

0.864.46
LowHigh

Fundamentals

  • Previous Close 1.88
  • Market Cap798.03M
  • Volume8636227
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-194.57400M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -150.15200M
  • Diluted EPS TTM-0.83

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -190.88600M -257.14700M -327.26500M -332.63200M -257.00500M
Minority interest - - - - -
Net income -190.88600M -257.59000M -327.26500M -329.81500M -244.83700M
Selling general administrative 56.78M 65.20M 71.67M 79.31M 74.11M
Selling and marketing expenses - - - - -
Gross profit -12.35900M 0.02M 0.10M 0.24M 38.49M
Reconciled depreciation 12.36M 13.64M 13.79M 14.29M 10.45M
Ebit -206.93300M -256.96600M -327.26500M -349.74400M -266.24600M
Ebitda -194.57400M -243.32700M -313.06600M -335.44900M -255.79200M
Depreciation and amortization 12.36M 13.64M 14.20M 14.29M 10.45M
Non operating income net other - - - - -1.21300M
Operating income -206.93300M -273.19900M -327.73700M -335.44900M -255.79200M
Other operating expenses 206.93M 273.22M 327.83M 335.69M 294.28M
Interest expense 1.07M 0.18M 17.11M -17.11200M 10.45M
Tax provision 0.00000M 0.44M 0.00000M - 0.00000M
Interest income 19.29M 20.15M 14.80M 4.57M 1.71M
Net interest income 18.21M 19.97M 14.80M 4.57M 1.71M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.44M -2.81700M -2.81700M -12.16800M
Total revenue 0.00000M 0.02M 0.10M 0.24M 38.49M
Total operating expenses 194.57M 273.22M 327.83M 335.69M 294.28M
Cost of revenue 12.36M 13.64M 14.20M - -
Total other income expense net 16.05M 16.05M 0.47M 2.82M -1.21300M
Discontinued operations - - - - -
Net income from continuing ops -190.88600M -257.59000M -332.85500M -332.63200M -257.00500M
Net income applicable to common shares - - - -332.63200M -257.00500M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 415.90M 548.71M 642.84M 817.08M 1038.63M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.04M 9.01M 10.42M 11.50M 14.02M
Total liab 123.36M 126.53M 130.60M 151.21M 122.23M
Total stockholder equity 292.54M 422.18M 512.23M 665.87M 916.41M
Deferred long term liab - - - - -
Other current liab 28.24M 22.62M 24.32M 33.74M 37.50M
Common stock 0.23M 0.21M 0.17M 0.14M 0.14M
Capital stock 0.23M 0.21M 0.17M 0.14M 0.14M
Retained earnings -2010.70900M -1819.82300M -1562.23300M -1235.98000M -903.34800M
Other liab - - - 1.57M 4.12M
Good will - - - - -
Other assets - - - 16.86M 16.11M
Cash 51.69M 75.22M 83.16M 576.47M 809.48M
Cash and equivalents - - - - -
Total current liabilities 32.51M 35.52M 37.08M 54.52M 48.17M
Current deferred revenue - - 0.09M 0.89M 0.42M
Net debt 23.36M 15.54M 11.97M -481.34900M -739.55200M
Short term debt - 7.51M 6.78M 6.00M -
Short long term debt - - - - -
Short long term debt total 75.05M 90.76M 95.12M 95.12M 69.93M
Other stockholder equity 2302.75M 2241.88M 2075.25M 1911.63M 1822.18M
Property plant equipment - - - 196.43M 122.99M
Total current assets 257.75M 303.39M 459.12M 528.82M 809.48M
Long term investments 8.04M 80.67M 3.65M 71.97M 352.18M
Net tangible assets - - - 665.87M 916.41M
Short term investments 198.52M 217.26M 365.54M 455.42M 283.99M
Net receivables 1.50M 1.90M - 3.30M 5.82M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 4.27M 5.39M 5.90M 13.89M 10.26M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.27M -0.08900M -0.95500M -9.92600M -2.56700M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.14M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -903.34800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 37.39M 33.39M 16.90M 32.67M -322.05100M
Deferred long term asset charges - - - - -
Non current assets total 158.16M 245.32M 183.72M 288.25M 229.15M
Capital lease obligations 83.25M 90.76M 95.12M 101.12M 69.93M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 95.94M 75.69M 145.43M 106.16M 185.10M
Change to liabilities - - - 5.33M 3.93M
Total cashflows from investing activities 95.56M 75.69M 163.29M 106.16M 163.66M
Net borrowings - - - - -
Total cash from financing activities 30.16M 116.67M 95.69M 2.95M 11.96M
Change to operating activities - - - -1.62400M 7.25M
Net income -190.88600M -257.59000M -327.26500M -332.63200M -257.00500M
Change in cash -23.53000M -7.93700M 21.25M -111.41000M -9.19400M
Begin period cash flow 85.51M 93.45M 72.20M 183.61M 192.80M
End period cash flow 61.98M 85.51M 93.45M 72.20M 183.61M
Total cash from operating activities -149.24600M -200.30000M -237.73300M -220.51900M -184.81200M
Issuance of capital stock 22.35M 112.05M 91.11M 0.00000M 0.00000M
Depreciation 12.36M 13.64M 14.20M 14.29M 10.45M
Other cashflows from investing activities - - 111.35M - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 0.90M 1.53M 2.46M 2.46M 3.62M
Other cashflows from financing activities 6.91M 2.28M 4.58M 106.16M 8.35M
Change to netincome - - - 94.11M 80.82M
Capital expenditures 0.39M 0.69M 1.52M 5.19M 21.45M
Change receivables - - - - -
Cash flows other operating - - - - -29.96100M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -9.19400M
Change in working capital -10.87700M -24.79900M -15.30500M 3.71M -32.08900M
Stock based compensation 37.64M 51.74M 65.95M 83.60M 80.82M
Other non cash items 2.52M 16.26M 24.69M 2.43M 2.61M
Free cash flow -149.63200M -200.99400M -239.24900M -225.71000M -206.25800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALLO
Allogene Therapeutics Inc		 0.02 1.06% 1.90 - - 7784.36 2.85 3859.62 -1.0393
NVO
Novo Nordisk A/S		 -0.08 0.18% 43.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.99 4.74% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.115 0.03% 444.93 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.66 0.11% 612.14 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics Inc

210 East Grand Avenue, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. Co-Founder & Exec. Chairman 1949
Dr. David D. Chang M.D., Ph.D. Co-Founder, Pres, CEO & Director 1960
Mr. Joshua A. Kazam Co-Founder & Director 1977
Dr. Eric Thomas Schmidt Ph.D. Chief Financial Officer 1970
Dr. Alison Moore Ph.D. Chief Technical Officer 1967
Mr. Veer Bhavnagri Gen. Counsel & Compliance Officer 1983
Dr. Rafael G. Amado M.D. Exec. VP of R&D 1964
Ms. Barbra Sasu Chief Scientific Officer NA
Mr. Stephen Cheng Chief Information Officer NA
Ms. Christine Cassiano Chief Communications Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.